3Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B ( CALGB 8461 ). Blood, 2002, 100:4325-4336.
4Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the fit3 gene found in acute myeloid leukemia. Leukemia, 1996, 10:1911-1918.
5Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med, 2005, 352:254-266.
6Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood, 2010, 116: 5089-5102.
7Martelli MP, Pettirossi V, Thiede C, et al. CD34^+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood, 2010,116 : 3907-3922.
8Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 2006,107:4011-4020.
9Gale RE, Green C, Alien C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 2008, 111:2776-2784.
10Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 2005, 106 : 3733-3739.
